The [**Health Innovation Network**](http://hin-southlondon.org/)is the Academic Health Science Network (AHSN) for south London and part of the national [**AHSN** **Network**](http://www.ahsnnetwork.com/).These Terms and Conditions set out what companies and individuals with innovations (innovators) can expect from working with the Academic Health Science Networks (AHSNs) and what we expect in turn.

## **Definitions**

An innovator is a person or organisation developing a product or service. The term ‘innovator’ includes companies, academics and clinicians as well as individuals planning to register a company who have not yet done so.

An innovation is a product or service bringing new benefits to the payer, user or patient.

# Aims and Objectives

## What to expect from us:

1.1 We provide a range of support services to innovators and innovations which have potential to improve patient outcomes, reduce overall NHS expenditure and grow the UK health sector economy.

1.2 Innovators which lack the potential to reach the market, are likely to increase NHS costs, or are primarily based overseas are likely to fall outside the scope of work carried out by AHSNs.

1.3 All decisions on whether to provide any form of support are made at the sole discretion of the AHSN.

## What we expect from you:

* 1. Innovators must be open and honest about their evidence base and cost structures.
	2. Innovators must recognise that AHSNs are not commissioners or service providers and are therefore not themselves potential buyers of products or services.
	3. Innovators must inform an AHSN if they are already working with a different AHSN; this is not necessarily a barrier but enables us to avoid wasteful duplication of effort.

# About your Innovation

## What to expect from us:

* 1. Only information about your innovation which is already in the public domain will be shared publicly unless explicit consent is given by the innovator.
	2. Information shared by the innovator with any AHSN for supporting product development, spread, evaluation or adoption may be shared with other AHSNs and or NHS bodies for those purposes, unless that sharing is restricted by a Non-Disclosure Agreement (NDA) at the request of the innovator.
	3. An AHSN will sign appropriate NDAs to protect innovators Intellectual Property (IP). NDAs must be prepared and presented by the innovator for consideration by the AHSN. Generally we suggest that you do not share commercially sensitive information.
	4. All advice is offered in good faith to the best of an AHSNs understanding of the market place and innovator’s circumstances.

## What We Expect from You

* 1. Innovators requiring an NDA will prepare and provide a draft agreement for the AHSN to consider.

# About the support we offer

## What to expect from us:

# As a publicly funded bodies each AHSN reports back to our commissioners on how our funding is spent (i.e. how many innovators receiving how much support). Each AHSN keeps appropriate records to enable that reporting.

* 1. As a publicly funded bodies, AHSNs may publicise the support given to innovators, and the outcome of that support through public channels such annual reports, public presentations, newsletters and social media posts. Our reporting will be consistent with 2.1 (i.e., we will not disclose confidential information without prior consent from the innovator).
	2. Each AHSN may pro-actively inform innovators of relevant opportunities e.g., grant funding, educational events, networking meetings etc. AHSNs will maintain records to enable appropriate communications.
	3. Whilst we can signpost to sources of funding to assist in the development of your innovation and its readiness for market, we are not a direct funding body.

# All advice offered by an AHSN is subjected to due diligence by the innovator before implementation.

# Our data collection and retention is in accordance with UK data regulations (GDPR).

## What we expect from you:

* 1. As a publicly funded bodies, each AHSN reports back to our commissioners on the impact that our support has. We ask that innovators complete a questionnaire 2-3 times per year for up to 2 years after the end of our interactiontohelp AHSNs and our commissioners understand the impact of AHSN support.
	2. Innovators may publicise that they are working with one or more AHSNs but may not state or imply that our support (e.g. to develop, pilot or evaluate) constitutes endorsement of the product or its potential benefits without explicit written permission.
	3. Where support from one or more AHSNs helps achieve demonstrable outcomes (e.g. funding, evaluations, contracts) then that support should be publicly acknowledged by the innovator.